New study aims to perfect antifungal dosing for sickest ICU patients
NCT ID NCT04868188
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 32 adults in the ICU on ECMO life support who had severe influenza or COVID-19 and a serious fungal lung infection called aspergillosis. Researchers measured how the antifungal drug voriconazole behaves in the body to find the best dose for these very ill patients. The goal was to improve treatment success and reduce side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASPERGILLOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospitals of Leicester
Leicester, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Could a different way of pedaling rebuild muscles after severe COVID-19?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test